TNFRSF1B and metabolic dysfunction-associated steatotic liver disease: Enhancement of TNF–α signalling may be critical in the pathogenesis of hepatic steatosis and fibrosis, blockade of TNFR1/TNFR2 signalling is a promising therapeutic target for NAFLD [35].